Temasek Participates in Series B Round in Locanabio
Posted on 12/15/2020
San Diego-based Locanabio, Inc. (formerly called Locana) is developing a new class of genetic medicines. The company is currently advancing programs in neurodegenerative, neuromuscular, and retinal diseases.
Locanabio raised a US$ 100 million Series B round. The financing was led by Vida Ventures with participation from new investors including RA Capital Management, Invus, Acuta Capital Partners and an investment fund associated with SVB Leerink and prior Locanabio investors ARCH Venture Partners, Temasek Holdings, Lightstone Ventures, UCB Ventures, and GV (Google Ventures).
The financing plans to help Locanabio’s portfolio of RNA-targeted gene therapies and expand the technology platform to pursue a broad range of therapeutic indications. Locanabio is currently developing therapies to treat multiple genetic diseases with no approved therapeutic alternatives, including Huntington’s disease, spinocerebellar ataxia type 1, myotonic dystrophy type 1, genetic forms of amyotrophic lateral sclerosis and retinal diseases.
